Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: Lessons from animal models

Current Opinion in Rheumatology

Volumn 25, Issue 2, 2013, Pages 254-259

  Schaper, Fleur ^a   Heeringa, Peter ^a   Bijl, Marc ^b   Westra, Johanna ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

animal models; anti HMGB1; autoimmune diseases; HMGB1; intervention

Indexed keywords

DEOXYRIBONUCLEASE II; GOLD NANOPARTICLE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTHRITIS; ARTICULAR CARTILAGE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CRUSH TRAUMA; CYTOKINE PRODUCTION; ENDOTOXEMIA; IN VITRO STUDY; INNATE IMMUNITY; ISCHEMIA; LIVER TOXICITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PAIN; POLYARTHRITIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; REPERFUSION INJURY; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84873413531     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835cee2d     Document Type: Review

References (52)

1. Calogero S, Grassi F, Aguzzi A, et al. The lackof chromosomal protein HMG1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22:276-280.
2. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192:565-570.
3. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251.
4. Youn JH, Oh YJ, Kim ES, et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human mono-cytes. J Immunol 2008; 180:5067-5074.
5. Hreggvidsdottir HS, Ostberg T, Wähämaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86:655-662.
6. Schiraldi M, Raucci A, Munoz LM, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209:551-563.
7. De Souza AW, Westra J, Limburg PC, et al. HMGB1 in vasculardiseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11:909-917.
8. Straino S, Di Carlo A, Mangoni A, et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 2008; 128:1545-1553.
9. Van Zoelen MAD, Yang H, Florquin S, et al. Role of Toll-like receptors 2 and 4, and the receptorfor advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009; 31:280-284.
10. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107:11942-11947.
11. Yang H, Lundbäck P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18:250-259.
12. Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redoxforms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209:1519-1528.
13. Kazama H, Ricci J, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29:21-32.
14. Hreggvidsdottir HS, Lundberg AM, Aveberger AC, et al. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 18:224-230.
15. Wähämaa H, Schierbeck H, Hreggvidsdottir HS, et al. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther 13:R136.
16. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis ofSLE. J Exp Med 2008; 205:3007-3018.
17. Dupire G, Nicaise C, Gangji V, Soyfoo MS. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome. Scand J Rheumatol 2012; 41:120-123.
18. Abdulahad DA, Westra J, Bijzet J, et al. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:R71.
19. Taniguchi N, Kawahara K, Yone K, et al. High mobility group boxchromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48:971-981.
20. Af Klint E, Grundtman C, Engström M, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum 2005; 52:3880-3889.
21. Abdulahad DA, Westra J, Bijzet J, et al. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012; 14:R184.
22. Tian J, Avalos AM, Mao S, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8:487-496.
23. Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011; 270:309-318.
24. Zetterström CK, Jiang W, Wähämaa H, et al. Pivotal advance: inhibition of HMGB1 nucleartranslocation asa mechanismfortheantirheumaticeffectsof gold sodium thiomalate. J Leukoc Biol 2008; 83:31-38.
25. Tsai C, Lu S, Hu C, et al. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 2012; 188:68-76.
26. Schierbeck H, Wähämaa H, Andersson U, Harris HE. Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol Med 2010; 16:343-351.
27. Ostberg T, Wähämaa H, Palmblad K, et al. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther2008; 10:R1.
28. Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48:2052-2058.
29. Schierbeck H, Lundback P, Palmblad K, et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011; 17:1039-1044.
30. Ostberg T, Kawane K, Nagata S, et al. Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 2010; 62:2963-2972.
31. Tsoyi K, Jang HJ, Nizamutdinova IT, et al. Metformin inhibitsHMGB1 release in LPS-treated RAW 264. 7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011; 162:1498-1508.
32. Vicentino AR, Carneiro VC, Amarante Ade M, et al. Evaluation of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4, 5-dihydroisoxazole as a novel anti-inflammatory drug candidate. PLoS One 2012; 7:e39104.
33. Yang H, Ochani M, Li J, et al. Reversing established sepsiswith antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301.
34. Chavan SS, Huerta PT, Robbiati S, et al. HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 2012; 18:930-937.
35. Ha T, Xia Y, Liu X, et al. Glucan phosphate attenuates myocardial HMGB1 translocation in severe sepsis through inhibiting NF-kappaB activation. Am J Physiol Heart Circ Physiol 2011; 301:H848-H855.
36. Shimazaki J, Matsumoto N, Ogura H, et al. Systemicinvolvementofhigh- mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury. Shock 2012; 37:634-638.
37. Rabadi MM, Ghaly T, Goligorsky MS, Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 2012; 303:F873-F875.
38. Rabadi MM, Kuo MC, Ghaly T, et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol Renal Physiol 2012; 302:F730-F741.
39. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfu-sion injury. J Am Soc Nephrol 2010; 21:1878-1890.
40. Kojima D, Mera T, Nishinakamura H, et al. Prevention of high-mobility group box 1-mediated early loss of transplanted mouse islets in the liver by antithrombin III. Transplantation 2012; 93:983-988.
41. Kojima M, Tanabe M, Shinoda M, et al. Role of high mobility group box chromosomal protein 1 in ischemia-reperfusion injury in the rat small intes-tine. J Surg Res 2012; 178:466-471.
42. Antoine DJ, Williams DP, Kipar A, et al. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acet-aminophen hepatotoxicity. Mol Med 2010; 16:479-490.
43. Feldman P, Due MR, Ripsch MS, et al. The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain. J Neuroinflamm 2012; 9:180.
44. Otoshi K, Kikuchi S, Kato K, et al. Anti-HMGB1 neutralization antibody improves pain-related behavior induced by application of autologous nucleus pulposus onto nerve roots in rats. Spine 2011; 36:E692-E698.
45. Shibasaki M, Sasaki M, Miura M, et al. Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain 2010; 149:514-521.
46. Gao Q, Ma LL, Gao X, et al. TLR4 mediates early graft failure after intraportal islet transplantation. Am J Transplant 2010; 10:1588-1596.
47. Kanellakis P, Agrotis A, Kyaw TS, et al. High-mobility group box protein 1 neutralization reduces developmentofdiet-induced atherosclerosis in apolipo-protein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:313-319.
48. Kim I, Shin J, Kim S, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 2012; 20:829-839.
49. Zhang J, Takahashi HK, Liu K, et al. Antihigh mobility group box-1 monoclonal antibody protectsthe blood-brain barrierfrom ischemia-induced disruption in rats. Stroke 2011; 42:1420-1428.
50. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16:413-419.
51. Okuma Y, Liu K, Wake H, et al. Antihigh mobility group box-1 antibodytherapy fortraumatic brain injury. Ann Neurol 2012; 72373-72384.
52. Nadatani Y, Watanabe T, Tanigawa T, et al. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am J Pathol 2012; 181:98-110.